| |
RFS
|
|---|
| |
HR (95% CI)
|
p
|
|---|
|
Model 1a
| | |
|
TNM stage, Stage 0
|
1
|
0.067
|
|
Stage I
|
1.075 (0.423–2.729)
|
0.88
|
|
Stage II, III
|
1.983 (0.77–5.106)
|
0.156
|
|
Stage IV
|
0.906 (0.105–7.837)
|
0.929
|
|
FAM83H positive (vs. negative)
|
3.691 (1.977–6.889)
|
< 0.001
|
|
Model 2b
| | |
|
TNM stage, Stage 0
|
1
|
0.037
|
|
Stage I
|
1.175 (0.871–3.021)
|
0.738
|
|
Stage II, III
|
2.305 (0.871–6.1)
|
0.093
|
|
Stage IV
|
1.106 (0.128–9.584)
|
0.927
|
|
Combined expression, FAM83H−/Nectin1−
|
1
|
< 0.001
|
|
FAM83H−/Nectin1+ or FAM83H+/Nectin1−
|
3.877 (1.582–9.502)
|
0.003
|
|
FAM83H+/Nectin1+
|
5.272 (2.377–11.693)
|
< 0.001
|
- RFS relapse free survival, HR hazard ratio, 95% CI 95% confidence interval
- aVariables considered in model 1 were histologic grade, T stage, N stage, TNM stage, FAM83H expression, and Nectin1 expression
- bVariables considered in model 2 were histologic grade, T stage, N stage, TNM stage, and combined expression of FAM83H and Nectin1
